WALTHAM, Mass., March 9 /PRNewswire/ -- Compound Therapeutics, Inc., a biotechnology company developing a new generation of high-potency, targeted protein-based drugs, today announced the appointment of John Edwards as Vice President, Commercial Development. Mr. Edwards brings more than twenty years of experience in global development and commercialization of biopharmaceuticals to this new position where he will help lead Compound Therapeutics' operational and commercialization efforts.
"John's broad and deep experience with major biopharmaceutical companies and strong track record of building and leading successful businesses make him the ideal candidate to fill this critical role as we evolve our operating capabilities and advance our pre-clinical programs," said Frank Lee, President and CEO of Compound Therapeutics. "His unique combination of product development, manufacturing, and commercial operations experience will certainly help Compound Therapeutics accelerate our protein-based therapeutics to the marketplace."
Prior to joining Compound Therapeutics, Mr. Edwards served as Vice President, Sales, Marketing, and Medical Affairs at Transkaryotic Therapies. Additionally, during his 15 year tenure with Wyeth Pharmaceuticals/Genetics Institute, he held senior-level positions in R&D, manufacturing, and commercial operations at which time he built a $500 million global pharmaceutical business in hematology. Over the past 9 years Mr. Edwards has held senior-level positions in U.S. and global marketing were he successfully launched four products in three different therapeutic areas (hematology, oncology, organ transplantation).
"This is truly an exciting time to join Compound Therapeutics as we are focused on developing a new class of protein-based drugs with significant medical and commercial potential," said John Edwards, Compound Therapeutics' new Vice President, Commercial Development. "The 1980's saw the emergence of many important replacement biopharmaceuticals. The 1990's witnessed the commercialization of important antibodies and receptor-based proteins. I am pleased to join Compound Therapeutics and help develop of the next wave of biopharmaceutical proteins that will be not be limited by what is naturally available, but instead can be tailored for both specificity and potency to a desired therapeutic target."
About Compound Therapeutics
Compound Therapeutics, Inc., which received $12 million in series A Preferred Stock financing in March 2003, is a privately held biotechnology company developing the next generation of protein-based drugs through the use of an advanced product platform for engineering new proteins. The company's novel protein drugs are being developed with superior therapeutic properties, including higher potency, greater specificity, and less frequent dosing than conventional protein drugs. Using its robust drug discovery platform that includes its proprietary protein display technology, PROfusion(TM), Compound Therapeutics' research and development activities employ an advanced product platform for engineering new proteins in four select disease areas: oncology, inflammation, autoimmune disorders and infectious disease. The company's discovery platform is the foundation for a product-generating capability that synthesizes novel biotherapeutics including proprietary binding proteins, TRINECTINs(TM), and binding proteins linked to enzymes, called Target Addressable Enzymes (Adzymes). Compound Therapeutics is funded by three leading venture capital firms, Atlas Ventures, Flagship Ventures, and Polaris Ventures.
Compound Therapeutics, Inc.